<p>根据其最近向证券交易委员会提交的 13F 文件，Advent Capital Management DE 在第一季度购买了礼来公司（NYSE:LLY - 免费报告）的一项新股份。该公司购买了 3,500 股该公司的股票，价值约为 2,891,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>特朗普 GLP-1 试点计划可能会推动诺和诺德和礼来</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也调整了他们对 LLY 的持股。Garner Asset Management Corp 在第四季度将其在礼来公司的股份增加了 2.3%。Garner Asset Management Corp 现在拥有 532 股该公司的股票，价值 41.1 万美元，此前在上个季度又购买了 12 股。Tobias Financial Advisors Inc.在第四季度将其在礼来公司的股份增加了 4.1%。Tobias Financial Advisors Inc.现在拥有 307 股该公司的股票，价值 23.7 万美元，此前在上个季度又购买了 12 股。Redwood Investments LLC 在第四季度将其在礼来公司的股份增加了 0.5%。Redwood Investments LLC 现在拥有 2,209 股该公司的股票，价值 170.5 万美元，此前在上个季度又购买了 12 股。Hobbs Wealth Management LLC 在第一季度将其在礼来公司的股份增加了 0.8%。Hobbs Wealth Management LLC 现在拥有 1,459 股该公司的股票，价值 120.5 万美元，此前在上个季度又购买了 12 股。最后，Hixon Zuercher LLC 在第一季度将其在礼来公司的股份增加了 0.7%。Hixon Zuercher LLC 现在拥有 1,789 股该公司的股票，价值 147.7 万美元，此前在上个季度又购买了 12 股。当前 82.53% 的股票由机构投资者持有。</p>
<h2>礼来公司股票下跌 2.5%</h2>
<p>NYSE LLY 周五开盘价为 625.15 美元。该股票的 50 日移动平均线为 774.10 美元，200 日移动平均线为 799.11 美元。该公司的流动比率为 1.37，速动比率为 1.06，债务与股本比率为 2.18。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 972.53 美元。该股票的市值为 5924.8 亿美元，市盈率为 40.86，市盈增长比率为 0.89，贝塔值为 0.44。</p>
<ul>
<li>礼来公司 14% 的财报后下滑是否是买入机会？</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 8 月 7 日星期四发布了季度财报。该公司报告季度每股收益为 6.31 美元，超出分析师一致预期的 5.59 美元，超出幅度为 0.72 美元。礼来公司的股本回报率为 98.25%，净利润率为 25.91%。该公司季度收入为 155.6 亿美元，而分析师预期为 144 亿美元。在去年同期，该公司每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。研究分析师预测，礼来公司本财年的每股收益将达到 23.48 美元。</p>
<h2>礼来公司分红公告</h2>
<p>该公司最近还宣布了一项季度分红，将于 9 月 10 日星期三支付。8 月 15 日星期五的登记投资者将获得 1.50 美元的分红。该分红的除息日为 8 月 15 日星期五。这相当于每年 6.00 美元的分红，收益率为 1.0%。礼来公司的派息比率目前为 48.82%。</p>
<h2>内部买卖</h2>
<ul>
<li>诺和诺德股票下跌——但底部终于到了吗？</li>
</ul>
<p>在其他礼来公司的新闻中，董事 Jamere Jackson 在 8 月 8 日星期五的交易中购买了 200 股该股票。每股平均购买成本为 639.56 美元，总价值为 127,912.00 美元。收购后，该董事在公司中拥有 9,402 股，价值约为 6,013,143.12 美元。这笔交易代表了他们持股的 2.17% 的增加。该购买在向证券交易委员会提交的文件中披露，文件可通过此链接获取。公司内部人士持有该公司股票的 0.13%。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该公司进行了评论。汇丰银行将礼来公司的评级从 “买入” 下调至 “减持”，并将其目标价从 1,150.00 美元下调至 700.00 美元，相关研究报告于 4 月 28 日发布。汇丰全球研究将礼来公司的评级从 “强力买入” 下调至 “适度卖出”，相关研究报告于 4 月 28 日发布。摩根士丹利在 7 月 10 日的研究报告中重申了 “增持” 评级，并将礼来公司的目标价设定为 1,135.00 美元（上调自 1,133.00 美元）。Cantor Fitzgerald 在 4 月 22 日的研究报告中开始覆盖礼来公司，给予 “增持” 评级，并设定 975.00 美元的目标价。最后，Erste Group Bank 在 6 月 5 日的研究报告中将礼来公司的评级从 “买入” 下调至 “持有”。一位投资分析师对该股票给予了卖出评级，五位分析师给予了持有评级，十六位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 984.41 美元。</p>
<p><strong>获取我们对礼来公司的最新分析</strong></p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>ETF 是否支付股息？你需要知道的事项</li>
<li>Rocket Lab 发布第二季度业绩：牛市论点是否依然成立？</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
<li>安静期到期的解释</li>
<li>现在是购买 Cheniere Energy 的好时机：预计将创下新高</li>
</ul>
<p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Advent Capital Management DE 最近在礼来公司（NYSE: LLY）中获得了新的股份，购买了价值约 289 万美元的 3,500 股，具体情况在他们最近的 13F 文件中披露。其他机构投资者也增加了对礼来的持股。该股票目前下跌 2.5%，交易价格为 625.15 美元，市值为 5924.8 亿美元。礼来最近报告了强劲的季度收益，超出了分析师的预期，并宣布每股派发季度股息 1.50 美元</p>

<p>Advent Capital Management DE purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm purchased 3,500 shares of the company's stock, valued at approximately $2,891,000.</p>
<div class="lb-trans"><p>根据其最近向证券交易委员会提交的 13F 文件，Advent Capital Management DE 在第一季度购买了礼来公司（NYSE:LLY - 免费报告）的一项新股份。该公司购买了 3,500 股该公司的股票，价值约为 2,891,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 试点计划可能会推动诺和诺德和礼来</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Garner Asset Management Corp boosted its position in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after buying an additional 12 shares during the last quarter. Tobias Financial Advisors Inc. boosted its position in shares of Eli Lilly and Company by 4.1% during the fourth quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock valued at $237,000 after buying an additional 12 shares during the last quarter. Redwood Investments LLC boosted its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after buying an additional 12 shares during the last quarter. Hobbs Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after buying an additional 12 shares during the last quarter. Finally, Hixon Zuercher LLC boosted its position in shares of Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after buying an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了他们对 LLY 的持股。Garner Asset Management Corp 在第四季度将其在礼来公司的股份增加了 2.3%。Garner Asset Management Corp 现在拥有 532 股该公司的股票，价值 41.1 万美元，此前在上个季度又购买了 12 股。Tobias Financial Advisors Inc.在第四季度将其在礼来公司的股份增加了 4.1%。Tobias Financial Advisors Inc.现在拥有 307 股该公司的股票，价值 23.7 万美元，此前在上个季度又购买了 12 股。Redwood Investments LLC 在第四季度将其在礼来公司的股份增加了 0.5%。Redwood Investments LLC 现在拥有 2,209 股该公司的股票，价值 170.5 万美元，此前在上个季度又购买了 12 股。Hobbs Wealth Management LLC 在第一季度将其在礼来公司的股份增加了 0.8%。Hobbs Wealth Management LLC 现在拥有 1,459 股该公司的股票，价值 120.5 万美元，此前在上个季度又购买了 12 股。最后，Hixon Zuercher LLC 在第一季度将其在礼来公司的股份增加了 0.7%。Hixon Zuercher LLC 现在拥有 1,789 股该公司的股票，价值 147.7 万美元，此前在上个季度又购买了 12 股。当前 82.53% 的股票由机构投资者持有。</p>
</div><h2>Eli Lilly and Company Stock Down 2.5%</h2>
<div class="lb-trans"><h2>礼来公司股票下跌 2.5%</h2>
</div><p>NYSE LLY opened at $625.15 on Friday. The stock's 50 day moving average is $774.10 and its 200 day moving average is $799.11. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $972.53. The stock has a market cap of $592.48 billion, a PE ratio of 40.86, a P/E/G ratio of 0.89 and a beta of 0.44.</p>
<div class="lb-trans"><p>NYSE LLY 周五开盘价为 625.15 美元。该股票的 50 日移动平均线为 774.10 美元，200 日移动平均线为 799.11 美元。该公司的流动比率为 1.37，速动比率为 1.06，债务与股本比率为 2.18。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 972.53 美元。该股票的市值为 5924.8 亿美元，市盈率为 40.86，市盈增长比率为 0.89，贝塔值为 0.44。</p>
</div><ul>
<li>Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来公司 14% 的财报后下滑是否是买入机会？</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 98.25% and a net margin of 25.91%. The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the firm earned $3.92 EPS. The firm's revenue was up 37.6% compared to the same quarter last year. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 8 月 7 日星期四发布了季度财报。该公司报告季度每股收益为 6.31 美元，超出分析师一致预期的 5.59 美元，超出幅度为 0.72 美元。礼来公司的股本回报率为 98.25%，净利润率为 25.91%。该公司季度收入为 155.6 亿美元，而分析师预期为 144 亿美元。在去年同期，该公司每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。研究分析师预测，礼来公司本财年的每股收益将达到 23.48 美元。</p>
</div><h2>Eli Lilly and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>礼来公司分红公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 1.0%. Eli Lilly and Company's payout ratio is currently 48.82%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 9 月 10 日星期三支付。8 月 15 日星期五的登记投资者将获得 1.50 美元的分红。该分红的除息日为 8 月 15 日星期五。这相当于每年 6.00 美元的分红，收益率为 1.0%。礼来公司的派息比率目前为 48.82%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德股票下跌——但底部终于到了吗？</li>
</ul>
</div><p>In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Corporate insiders own 0.13% of the company's stock.</p>
<div class="lb-trans"><p>在其他礼来公司的新闻中，董事 Jamere Jackson 在 8 月 8 日星期五的交易中购买了 200 股该股票。每股平均购买成本为 639.56 美元，总价值为 127,912.00 美元。收购后，该董事在公司中拥有 9,402 股，价值约为 6,013,143.12 美元。这笔交易代表了他们持股的 2.17% 的增加。该购买在向证券交易委员会提交的文件中披露，文件可通过此链接获取。公司内部人士持有该公司股票的 0.13%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts recently commented on the company. HSBC cut Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;reduce&#34; rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Hsbc Global Res cut Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;moderate sell&#34; rating in a research report on Monday, April 28th. Morgan Stanley reissued an &#34;overweight&#34; rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an &#34;overweight&#34; rating and a $975.00 target price on the stock. Finally, Erste Group Bank cut Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, June 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $984.41.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司进行了评论。汇丰银行将礼来公司的评级从 “买入” 下调至 “减持”，并将其目标价从 1,150.00 美元下调至 700.00 美元，相关研究报告于 4 月 28 日发布。汇丰全球研究将礼来公司的评级从 “强力买入” 下调至 “适度卖出”，相关研究报告于 4 月 28 日发布。摩根士丹利在 7 月 10 日的研究报告中重申了 “增持” 评级，并将礼来公司的目标价设定为 1,135.00 美元（上调自 1,133.00 美元）。Cantor Fitzgerald 在 4 月 22 日的研究报告中开始覆盖礼来公司，给予 “增持” 评级，并设定 975.00 美元的目标价。最后，Erste Group Bank 在 6 月 5 日的研究报告中将礼来公司的评级从 “买入” 下调至 “持有”。一位投资分析师对该股票给予了卖出评级，五位分析师给予了持有评级，十六位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 984.41 美元。</p>
</div><p><strong>Get Our Latest Analysis on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>获取我们对礼来公司的最新分析</strong></p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
<li>Quiet Period Expirations Explained</li>
<li>Now Is a Great Time to Buy Cheniere Energy: New High Expected</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>ETF 是否支付股息？你需要知道的事项</li>
<li>Rocket Lab 发布第二季度业绩：牛市论点是否依然成立？</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
<li>安静期到期的解释</li>
<li>现在是购买 Cheniere Energy 的好时机：预计将创下新高</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Advent Capital Management DE 在礼来公司（NYSE:LLY）建立了价值 289 万美元的头寸